Gilead Sciences (NASDAQ:GILD) saw its stock climb in after-hours trading on Friday, following an upbeat quarterly performance and a raised full-year outlook, driven by resilient demand for its HIV therapies.
For the second quarter, the company reported adjusted earnings of $2.01 per share on revenue of $7.1 billion—both figures topping Wall Street expectations, which stood at $1.96 per share and $6.97 billion in revenue, respectively.
Sales of HIV-related products rose 7% year-over-year to reach $5.1 billion, providing a strong buffer against increased R&D expenditures during the quarter.
“Gilead’s HIV business was firing on all cylinders this quarter as both Biktarvy and Descovy performed ahead of consensus expectations,” BMO Capital Markets analysts noted. Although the company did not disclose sales for Yeztugo—an HIV prevention drug approved by U.S. regulators in June—analysts believe that the strong overall performance of its HIV portfolio is boosting investor confidence.
In response to the solid results, Gilead raised its full-year 2025 guidance. The company now expects adjusted earnings per share in the range of $7.95 to $8.25, compared to its previous forecast of $7.70 to $8.10.
Total product sales are also projected to be stronger than previously anticipated, with the new range set at $28.3 billion to $28.7 billion, up slightly from the earlier estimate of $28.2 billion to $28.6 billion.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.